$7.13
-0.045-0.63%
Last update: Dec 15, 2:43 PM
Comments
Loading...
Xeris Biopharma Holdings Stock Guidance
XERSNASDAQ
Xeris Biopharma Holdings Stock Guidance | NASDAQ:XERS | Benzinga
Xeris Biopharma Holdings issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 11/06/2025 | XERS | Xeris Biopharma Holdings | FY | 2025 | — | — | — | $285.00M | $290.00M | $286.75M | Get Alert |
| 08/07/2025 | XERS | Xeris Biopharma Holdings | FY | 2025 | — | — | — | $280.00M | $290.00M | $270.01M | Get Alert |
| 06/03/2025 | XERS | Xeris Biopharma Holdings | FY | 2030 | — | — | — | $750.00M | $750.00M | — | Get Alert |
| 06/03/2025 | XERS | Xeris Biopharma Holdings | FY | 2025 | — | — | — | $260.00M | $275.00M | $269.16M | Get Alert |
| 05/08/2025 | XERS | Xeris Biopharma Holdings | FY | 2025 | — | — | — | $260.00M | $275.00M | $262.30M | Get Alert |
| 03/06/2025 | XERS | Xeris Biopharma Holdings | FY | 2025 | — | — | — | $255.00M | $275.00M | $239.77M | Get Alert |
| 01/10/2025 | XERS | Xeris Biopharma Holdings | FY | 2024 | — | — | — | $203.00M | $203.00M | $199.70M | Get Alert |
| 01/10/2025 | XERS | Xeris Biopharma Holdings | Q4 | 2024 | — | — | — | $60.00M | $60.00M | $56.74M | Get Alert |
| 11/08/2024 | XERS | Xeris Biopharma Holdings | FY | 2024 | — | — | — | $198.00M | $202.00M | $193.40M | Get Alert |
| 08/08/2024 | XERS | Xeris Biopharma Holdings | FY | 2024 | — | — | — | $190.00M | $200.00M | $187.35M | Get Alert |
| 07/08/2024 | XERS | Xeris Biopharma Holdings | Q2 | 2024 | — | — | — | $47.00M | — | $44.89M | Get Alert |
| 05/09/2024 | XERS | Xeris Biopharma Holdings | FY | 2024 | — | — | — | $175.00M | $200.00M | $184.43M | Get Alert |
| 03/06/2024 | XERS | Xeris Biopharma Holdings | FY | 2024 | — | — | — | $170.00M | $200.00M | $188.01M | Get Alert |
| 01/04/2024 | XERS | Xeris Biopharma Holdings | FY | 2023 | — | — | — | $165.00M | $165.00M | $161.96M | Get Alert |
| 11/09/2023 | XERS | Xeris Biopharma Holdings | FY | 2023 | — | — | — | $160.00M | $165.00M | $158.23M | Get Alert |
| 10/16/2023 | XERS | Xeris Biopharma Holdings | FY | 2023 | — | — | — | $155.00M | $165.00M | $158.23M | Get Alert |
| 08/08/2023 | XERS | Xeris Biopharma Holdings | FY | 2023 | — | — | — | $145.00M | $165.00M | $149.35M | Get Alert |
| 05/09/2023 | XERS | Xeris Biopharma Holdings | FY | 2023 | — | — | — | $135.00M | $165.00M | $146.90M | Get Alert |
| 03/08/2023 | XERS | Xeris Biopharma Holdings | FY | 2023 | — | — | — | $135.00M | $165.00M | $152.31M | Get Alert |
FAQ
Q
What is the most recent guidance for Xeris Biopharma Holdings (XERS)?
A
There have been no specific sales or earnings guidance reported for Xeris Biopharma Holdings in recent months.
Browse guidance and forecast on all stocks.
People Also Watch
Market Resources
Trading Tools & Education
- Benzinga Pro Trading Platform
- Options Trading Strategies and News
- Stock Market Trading Ideas and Analysis
- Technical Analysis Charts and Indicators
- Fundamental Analysis and Valuation
- Day Trading Guides and Strategies
- Live Investors Events
- Pre market Stock Analysis and News
- Cryptocurrency Market Analysis and News
Ring the Bell
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.
© 2025 Benzinga | All Rights Reserved